← Leaderboards
Camila Margarita Manrique Acevedo
Harry S. Truman Memorial Va Hospital
$5,456,962
Attributed
$6,263,073
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,263,073 · 4
VA$0 · 2
By mechanism
R01$4,879,405 · 2
K08$802,418 · 1
R21$581,250 · 1
I01$0 · 2
Top collaborators
- Jaume Padilla6 shared
- Luis A Martinez-Lemus2 shared
Most similar at Harry S. Truman Memorial Va Hospital
Same institution · by research overlap
- Jaume Padilla$7,120,291
- William P Fay$8,557,177
- Shiyou Chen$16,685,151
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesBlood VesselsNon-Insulin-Dependent Diabetes MellitusDiabeticPreventFemaleMaleMediatingObesityWomanPostmenopausePathway InteractionsSignal TransductionCardiovascular Disorder RiskEndothelial CellsFructoseInsulin ResistanceCharacteristicsIn VivoEndotheliumArterial StiffnessMouse ModelAgingFeeding
Grant awards (20)
SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$591,486
R01 · FY2025 · AG · contact PI
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans with Obesity$0
I01 · FY2025 · VA
SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$617,681
R01 · FY2024 · AG · contact PI
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes$0
I01 · FY2024 · VA · contact PI
Estrogen receptor alpha signaling in endothelial cells exacerbates arterial stiffening via upregulation of ENaC in insulin resistant females$614,943
R01 · FY2023 · HL · contact PI
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes$0
I01 · FY2023 · VA · contact PI
Estrogen receptor alpha signaling in endothelial cells exacerbates arterial stiffening via upregulation of ENaC in insulin resistant females$735,403
R01 · FY2022 · HL · contact PI
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes$0
I01 · FY2022 · VA · contact PI
Estrogen receptor alpha signaling in endothelial cells exacerbates arterial stiffening via upregulation of ENaC in insulin resistant females$858,380
R01 · FY2021 · HL · contact PI
Estrogen receptor alpha signaling in endothelial cells exacerbates arterial stiffening via upregulation of ENaC in insulin resistant females$687,369
R01 · FY2020 · HL · contact PI
Sex-related differences in arterial stiffness in type 2 diabetics: role of uric acid$193,750
R21 · FY2020 · DK · contact PI
Estrogen receptor alpha signaling in endothelial cells exacerbates arterial stiffening via upregulation of ENaC in insulin resistant females$106,001
R01 · FY2020 · HL · contact PI
Estrogen receptor alpha signaling in endothelial cells exacerbates arterial stiffening via upregulation of ENaC in insulin resistant females$668,142
R01 · FY2019 · HL · contact PI
Sex-related differences in arterial stiffness in type 2 diabetics: role of uric acid$193,750
R21 · FY2019 · DK · contact PI
Mineralocorticoid and estrogen receptor alpha signaling in the pathogenesis of vascular stiffness in insulin resistant females$169,376
K08 · FY2019 · HL · contact PI
Sex-related differences in arterial stiffness in type 2 diabetics: role of uric acid$193,750
R21 · FY2018 · DK · contact PI
Mineralocorticoid and estrogen receptor alpha signaling in the pathogenesis of vascular stiffness in insulin resistant females$168,372
K08 · FY2018 · HL · contact PI
Mineralocorticoid and estrogen receptor alpha signaling in the pathogenesis of vascular stiffness in insulin resistant females$167,400
K08 · FY2017 · HL · contact PI
Mineralocorticoid and estrogen receptor alpha signaling in the pathogenesis of vascular stiffness in insulin resistant females$166,460
K08 · FY2016 · HL · contact PI
Mineralocorticoid and estrogen receptor alpha signaling in the pathogenesis of vascular stiffness in insulin resistant females$130,810
K08 · FY2015 · HL · contact PI